Identification of actionable genetic alteration for Type2 endometrial cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K16891
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: National Cancer Center Japan
• Principal Investigator: Kato Mayumi 国立研究開発法人国立がん研究センター, 中央病院, 医員 (90869893)
• Project Period (FY): 2022-04-01 – 2024-03-31
• Keywords: FIGO2023 / ProMisE study / POLE変異 / p53

Outline of Final Research Achievements

This study aims to clarify whether the ProMisE classification is useful in non-endometrioid cancer, which is generally considered to have a poor prognosis, and to clarify whether the discrimination ability of the revised FIGO2023 with molecular classification (FIGO2023m) is superior compared to FIGO2008 and FIGO 2023 without molecular classification. In multivariate analysis of overall survival in 50 cases of non-endometrioid cancer, only ProMisE classification was a poor prognostic factor, and ProMisE classification was useful even in non-endometrioid cancer. Among the three FIGO classifications, FIGO2023m showed the best classification ability in AIC value, C-index, and time-dependent ROC curve. Even in advanced stages, p53 status was a poor prognostic factor. Molecular subtypes can be added to the staging criteria to allow better prognostic prediction in all stages. The development of a method to check POLE status that is widely available in hospitals around the world is necessary.

Free Research Field

婦人科腫瘍

Academic Significance and Societal Importance of the Research Achievements

国外ではTCGAによる全エクソンシークエンスといった大規模ゲノム解析が既に行われており,欧米では既に遺伝 子パネル検査が日常診療として実施されており,十万人レベルでの ゲノムデータがGENIEなどに公開されている. しかし,近年増加傾向にある日本人子宮体がんに対するゲノム解析はまだ開始されたばかりであり,令和元年から始まった遺伝子パネル検査は欧米と同等のレベルになるにはまだ年月を必要としている.本研究は日本人に対するゲノム医療を推進させるための重要な研究データとなり得た.臨床現場への分子分類の導入も不可避となり安価で早急なPOLE変異検出の技術が待たれる.